On October 5, Vaxcyte, Inc. rose 53.91% in Regular Trading, trading at $87.055, following positive Phase 3 trial results for its experimental VAX-31 pneumococcal vaccine candidate. The vaccine met all primary immunogenicity endpoints compared to Prevnar 20 and Capvaxive in a Phase 3 trial testing efficacy against invasive pneumococcal disease and pneumonia. VAX-31 demonstrated favorable safety profiles across all age groups studied.

These trial results will form the basis for planned biologics license application submissions to the FDA in the first half of 2028. The company expects to report results from two additional adult Phase 3 trials in the first half of 2027.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)